Table 3 Attitude toward pharmacogenetic testing
Item | Strongly agree | Agree | Neither | Disagree | Strongly disagree |
|---|---|---|---|---|---|
Pharmacogenetic testing is a promising innovation in medicine and drug therapy | 223 (55.9%) | 137 (34.3%) | 17 (4.3%) | 17 (4.3%) | 5 (1.3%) |
Pharmacogenetic testing can offer a useful tool to the way I usually recommend medications | 201 (50.4%) | 159 (39.8%) | 18 (4.5%) | 14 (3.5%) | 7 (1.8%) |
I will utilize pharmacogenetic test results when practice guidelines for the use and interpretation of these tests are available | 198 (49.6%) | 158 (39.6%) | 19 (4.8%) | 20 (5.0%) | 4 (1.0%) |
Pharmacogenetic testing is advantageous in case of non-response to an essential drug (e.g.,, analgesic) | 232 (58.1%) | 129 (32.3%) | 14 (3.5%) | 19 (4.8%) | 5 (1.3%) |
Pharmacogenetic testing is more important in the hospital setting rather than the community pharmacy setting | 189 (47.4%) | 167 (41.9%) | 17 (4.3%) | 19 (4.8%) | 7 (1.8%) |
The interpretation of the pharmacogenetic testing information is difficult | 166 (41.6%) | 175 (43.9%) | 27 (6.8%) | 26 (6.5%) | 5 (1.3%) |
Pharmacogenetic testing will potentially help decrease the number of adverse drug events | 168 (42.1%) | 146 (36.6%) | 43 (10.8%) | 37 (9.3%) | 5 (1.3%) |
Pharmacogenetic testing will potentially help decrease the risk of drug–drug interaction | 136 (34.1%) | 134 (33.6%) | 59 (14.8%) | 63 (15.8%) | 7 (1.8%) |
Pharmacogenetic test results should be utilized when information about the test is included in the package inserts | 197 (49.4%) | 161 (40.4%) | 16 (4.0%) | 19 (4.8%) | 6 (1.5%) |
Patients should be educated about the purpose, benefits, limitations, and risks of pharmacogenetic testing | 175 (43.9%) | 166 (41.6%) | 27 (6.8%) | 25 (6.3%) | 6 (1.5%) |
I am concerned that unauthorized personnel may gain access to the results of the pharmacogenetic test | 144 (36.1%) | 154 (38.6%) | 31 (7.8%) | 61 (15.3%) | 9 (2.3%) |
I am concerned about the effect of the test results on my patients' eligibility for private health insurance | 152 (38.1%) | 139 (34.8%) | 35 (8.8%) | 59 (14.8%) | 14 (3.5%) |
I will be reluctant to adopt/utilize pharmacogenetic test results until I see it working for patients | 223 (55.9%) | 139 (34.8%) | 13 (3.3%) | 19 (4.8%) | 5 (1.3%) |
Pharmacogenetic testing is not compatible with my personal values | 140 (35.1%) | 138 (34.6%) | 28 (7.0%) | 81 (20.3%) | 12 (3.0%) |